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Purpose: Irritable bowel syndrome is a common gastrointestinal disorder with a global pre-
valence of approximately 11%. Onset or worsening of symptoms following digestion is one of
the characteristics of the condition. The present study aimed at evaluating the postprandial
sensory and motor response before and after treatment with sacral nerve modulation.
Patients and Methods: Twenty-one irritable bowel syndrome patients, 12 diarrhea-
predominant and 9 mixed, were eligible for a 6-week sacral nerve modulation test period.
Patients were investigated with multimodal impedance planimetry including a standardized
meal at baseline and at the end of 2 weeks of suprasensory stimulation embedded in the
6-week sacral nerve modulation period.
Results: There was no statistical significant difference in the sensory response to heat or
cold before and after sacral nerve modulation, p>0.05. At baseline, wall tension increased
after the meal (mean 124.79 [range 82.5 to 237.3] mmHg.mm before the meal, mean 207.76
[range, 143.5 to 429] mmHg.mm after the meal), p=0.048 indicating a postprandial response.
During sacral nerve modulation, the postprandial increase in wall tension did not reach
statistical significance (mean 86.79 [range 28.8 to 204.5] mmHg.mm before the meal, mean
159.71 [range 71.3 to 270.8] mmHg.mm after the meal), p=0.277. However, there was no
statistically significant difference between the postprandial wall tension at baseline and
during sacral nerve modulation, p=0.489. Likewise, we found no difference between pressure
or stretch ratio at baseline and during sacral nerve modulation, p>0.05.
Conclusion: Sacral nerve modulation does not exert its positive treatments effects in
diarrhea-predominant and mixed irritable bowel syndrome through a modulation of the
postprandial response.
Keywords: sacral nerve stimulation, sacral nerve modulation, postprandial response,
gastrocolic response, irritable bowel syndrome
Introduction
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal dis-
orders and accounts for around one-third of gastrointestinal complaints in general
practice.1 The syndrome consists of intermittent abdominal pain associated with
defecation and a change in stool frequency and consistency currently defined by the
Rome IV criteria.2 The etiology of IBS is unknown and therefore potential treat-
ment is based on symptom reduction. Most IBS patients experience a postprandial
onset or worsening of symptoms.3,4 Additionally, studies have found both an
abnormal motor and sensory postprandial response in IBS patients.5–7
Much effort has been put in finding a treatment with a long-lasting effect managing
as many of the IBS-specific symptoms as possible. Recent studies on sacral nerve
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modulation (SNM) for diarrhea-predominant and mixed IBS
(IBS-D and IBS-M) have found a positive, sustained treat-
ment effect regarding both IBS-specific symptoms and qual-
ity of life.8–10
SMN is administered through a surgically placed electrode
in the sacral foramina of S3 or S4, that delivers a continuous
low-intensity current to the sacral nerves. The electrode is
connected to a neurostimulator on the ipsilateral higher but-
tock and the combined system is operated through a personal
remote control. SNM is approved for fecal incontinence in
Europe and the United States. Evidence suggests that the
mode of action of SNM is by a direct efferent effect on the
anal sphincter complex as well as modulation of afferent input
to the sacral spinal cord and/or supraspinal centers.11–13
Multimodal impedance planimetry is a validated method
for investigations of rectal sensitivity and biomechanical
properties and has previously been described in detail.14
Moreover, the system has previously identified a hyperactive
postprandial response in patients with low anterior resection
syndrome following treatment for rectal cancer.15
The primary aim of the present study was to evaluate if
SNM has an effect on the postprandial response in IBS-D
and IBS-M patients.
Patients and Methods
Patients
The present study includes the IBS patients, whom between
October 1, 2013 and January 31, 2018 were included in
a randomized, double-blinded, cross-over study at our tertiary
clinic to evaluate the treatment effect of SNM in IBS patients,
(Figure 1).9 The diagnosis of IBS was performed according to
the Rome III criteria, 12 were subtyped with diarrhea-
predominant IBS and 9 with mixed IBS. There was no evi-
dence of lactose intolerance, celiac disease, or thyroid disease
in any of the patients and all had undergone a normal endo-
scopy including biopsies. Patients were acquired to
present with an average IBS-specific symptom score
(Gastrointestinal Symptom Rating Scale – Irritable Bowel
Syndrome (GSRS-IBS) version) of at least 40 points during
a 3-week period prior to enrollment. Exclusion criteria
IBS-D and IBS-M patients referred for possible inclusion in the 
double-blinded, placebo-controlled crossover study (n=67)
Excluded (n=46)
Not meeting inclusion criteria (n=18)
GSRS score < 40 points at baseline (n=3)
Pregnant (n=2)
Diverticulitis (n=1)
Bile acid malabsorption (n=2)
IBS-C (n=10)
Declined to participate (n=28)
IBS-D and IBS-M patients eligible for the double-blinded, 
placebo-controlled crossover study (n=21)
Patients investigated with multimodal stimulation (n=21)
Multimodal investigation patient sets eligible for analysis (n=20) 
Figure 1 Patient cohort.
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included constipation-predominant IBS, severe psychological
comorbidity, pregnancy, and age below 18 or above 70.
Study Design
The design of the study was a 6-week SNM period consisting
of a 4-week randomized, double-blinded, placebo-controlled
crossover study testing subsensory stimulation versus no
stimulation followed by a 2-week period of suprasensory
stimulation. Patients were investigated with multimodal
impedance planimetry at baseline before entering the study
and at the very end of the 2-week suprasensory SNM period.
The study was approved by the Danish Ethics Committee
(ID1-10-72-170-13) with every patient giving informed and
written consent before inclusion as well as conducted in
accordance with the Declaration of Helsinki. The study was
registered at Clinicaltrials.gov, NCT01950715.
Procedures
Sensory Assessment
Before initiating multimodal impedance planimetry, patients
were familiarized with the continuous electronic modified
visual analog scale (VAS) ranging from 0 to 10. The numbers
equaled 0 = no perception, 1 = vague perception, 2 = definite
perception of mild sensation, 3 = vague perception of mod-
erate sensation, 4 = definite perception ofmoderate sensation,
5 = pain detection threshold (PDT), 6 = slightly pain, 7 =mod-
erate pain detection threshold (MPDT), 8 = medium pain
intensity, 9 = intense pain, and 10 = unbearable pain. Earlier
studies have proven the scale applicable evaluating visceral
pain.16,17 The intensity of the sensory response was recorded
continuously for each type of stimulus during which patients
were informed to notify level 1, 3, 5, and 7. No stimulation
went beyond VAS 7.
Multimodal Stimulation
Procedures were undertaken with a custom-designed mul-
timodal probe. The non-compliant 30 µm thick and 70mm
long polyurethane bag attached 2cm under the tip had
a maximum diameter of 11.5cm and maximum recordable
cross-sectional area (CSA) of 10.380mm2.
An enema (Klyx; Ferring, Copenhagen, Denmark) was
given thirty minutes prior to procedures. The patient there-
after lay in a bed following which, the multimodal probe
was advanced through an anoscope (WelchAllyn,
Skaneateles Falls, NY, USA) to a final position 18 cm
from the anal verge. Stimulations then followed protocol
in the given order; thermal, mechanical, standardized
breakfast, mechanical.
For thermal stimulation, the bag was filled with 60mL of
0.9% saline to ensure mucosal contact. Hereafter, 4 C (cold)
or 68 °C (heat) 0.9% saline were administered recirculating
the saline from a closed circuit including either an ice-cubed
filled container or a stirred water bath (Grant GD100; Grant
Instruments, Cambridge, UK). The inlet rate of saline was
set to 150mL/min controlled by a peristaltic pump (Type
110ACR; Ole Dich Instrumentmakers, Hvidovre, Denmark),
which gave a temperature incline rate of 0.5 °C/s.
Temperatures in the bag were at all times noted using
a sensor (Buhl and Bønsøe AS, Virum, Denmark) and ana-
lyzed according to sensory levels (VAS 1–7).
For mechanical stimulation, the bag was filled with 0.9%
saline (37 °C) at a continuous flow rate of 200mL/min admi-
nistered by the peristaltic pump. Embedded in the probe, a six-
electrode impedance measuring systemmade real time record-
ing of two CSA´s. The system included two pairs of detection
electrodes placed with an inter-distance of 2mmmeasuring the
CSA1 and CSA2. On each side of the pairs of detection
electrodes an outer stainless steel excitation electrode was
receiving a constant AC current from a connected impedance
planimetry box (Ditens, A/S, Egaa, Denmark). The pressure
was obtained by a low-compliance perfusion system (Edwards
Lifesciences, Irvine, CA, USA) applying an external pressure
transducer. For mechanical and sensory preconditioning, three
distensions were performed and stopped at PDT (VAS 5).
Hereafter, a single distension was performed and stopped at
MPDT (VAS 7). CSA´s were calculated as the mean of CSA1
and CSA2 (mm2). Strain was defined as the wall circumfer-
ential length between minimum [the circumferential length at
VAS 1] and maximum distension [circumferential length at
VAS 7], divided by the length at minimum distension (unit-
less). CSA´s, strain, and wall tension (mmHg.mm) were all
analysed according to sensory levels (VAS 1–7). The precon-
ditioning and the following single distension reaching MPDT
was repeated after a standardized meal.
The standardized continental breakfast contained 1991 kJ
(14.2% protein, 44.9% fat, and 40.9% carbohydrates). The
meal was ingested after a minimum fast of 8 hours. The
mechanical stimulation was repeated twenty minutes after
consumption.
Statistical Analyses
The sample size calculation in the study was based on evaluat-
ing the clinical effect of SNM in the previously published,
randomized, double-blinded, placebo-controlled crossover
study.9
Dovepress Fassov et al
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For comparison of sensory data, we performed two-
way repeated measures ANOVA. For evaluation of biome-
chanical properties, statistical testing was performed
according to the distribution of data with a paired t-test
or the Wilcoxon signed rank test.
Data are provided as median (25th percentile, 75th percen-
tile) and mean ± SD unless otherwise stated. For the statistical
analysis, we used the software package SigmaPlot for
Windows Version 11.0 (Systat Software, Inc, San Jose, CA,
USA). P-values less than 0.05 were considered statistically
significant.
Post hoc we performed power analysis for tension,
pressure, and stretch based on results in the present study
with α=0.05.
Results
Of the 21 patients included in the randomized, double-
blinded, placebo-controlled crossover study, 20 were eli-
gible for analysis completing both multimodal stimulation
at baseline and at the end of the two weeks of suprasen-
sory SNM, Figure 1. All patients had failed standard
treatment including, dietary adjustments and lifestyle
changes, conventional anti-diarrheal, in one case eluxado-
line (released in Denmark in April 2017), conventional
osmotic laxatives, and linaclotide. Data on the clinical
effect of SNM has been reported previously. In summary,
SNM significantly reduced pain and number of daily
bowel movements, while the overall IBS-specific symp-
tom score was only reduced with borderline significance
(p=0.0572). Fifteen out of 20 patients had a successful
suprasensory stimulation period.9
For patient characteristics, see Table 1.
We observed no procedure-related adverse effects. VAS 7
was reached for all patients at any stimuli administered.
Thermal Stimulation
There was no difference in the sensory response to neither
heat nor cold comparing multimodal stimulation at base-
line and at the end of the suprasensory SNM period
(p>0.05), Figure 2.
Mechanical Stimulation
Verification of a Postprandial Response
At baseline, median wall tension at VAS 1 increased sig-
nificantly following the meal, 207.76 (range, 143.5 to 429)
mmHg.mm, compared to before the meal, 124.79 (range
82.5 to 237.3) mmHg.mm, p=0.048.
SNM and the Postprandial Response
Tension
At the end of the suprasensory SNM period, we found no
statistically significant difference when comparing median
wall tension at VAS 1 before, 86.79 (range 28.8 to 204.5)
mmHg.mm and after the meal, 159.71 (range 71.3 to 270.8)
mmHg.mm, p=0.277. Nevertheless, there was no statistical
significant difference when comparing the postprandial wall
tension at VAS 1 at baseline and the end of the suprasensory
SNM period, p=0.489. This was also true for all other VAS
levels (p>0.05), Figure 3.
Pressure
There was no statistically significant difference in the
pressure changes from VAS 1 to VAS 7 when comparing
postprandial data at baseline and at the end of the supra-
sensory SNM period (p=0.358).
Stretch Ratio
The stretch ratio at VAS 7 after the meal at baseline was
not statistically significant different with the stretch ratio at
VAS 7 after the meal at the end of the suprasensory SNM
period (p=0.750), Figure 4.
Comparison of Difference Between Postprandial
Changes at Baseline and During Suprasensory SNM
There was no difference in the median tension difference
at VAS 7 (p=0.818), the median pressure difference at
Table 1 Patient Characteristics
Study Group N=20
Age (years, median range) 25 (21, 53)
Men/Women 6/14
Diarrhoea-predominant/mixed IBS 12/8
Baseline IBS-specific scores (median [range])
Total GSRS-IBS score 58.5 (41, 77)
Pain 10 (5, 17)
Bloating 16.5 (7, 21)
Constipation 8 (2, 12)
Diarrhoea 20.5 (10, 26)
Satiety 6 (2, 14)
Total IBS-IS score 132.5 (48, 163)
Fatigue 31.5 (6, 42)
Daily impaired activities 37 (17, 49)
Sleep 16 (5, 27)
Emotional distress 29.5 (7, 35)
Eating habits 21 (9, 28)
Note: Values are expressed as median and range.
Abbreviations: GSRS-IBS, Gastrointestinal Symptom Rating Scale – Irritable Bowel
version; IBS-IS, Irritable Bowel Syndrome – Impact Scale.
Fassov et al Dovepress
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VAS 7 (p=0.541), or the stretch ratio difference at VAS 7
(p=0.971).
Comparison of SNM Responders and
Non-Responders
Within the groups of SNM responders and non-responders,
we found no difference in tension, pressure, or stretch
when comparing baseline and suprasensory SNM data
before and after the meal (p>0.05).
Neither did we find any significant difference in
tension or pressure, when comparing SNM responders
to non-responders at baseline and at the end of the SNM
suprasensory stimulation period before and after the
meal (p>0.05). We did observe a significant difference
in mean stretch between SNM responders and non-
responders before the meal at both baseline 2.64±1.82
vs 1.44±0.21, p=0.04 and in the end of the suprasensory
stimulation period 3.00±2.07 vs.1.47±0.29, p=0.02.
Analysis of differences between groups were, however,
non-significant (p>0.05).
Power Analysis
Given n=20 and the observed differences and standard
deviations, the calculated power was 0.81 for tension,
0.86 for pressure, and 0.84 for stretch.
Figure 2 Change in temperature to Visual Analog Scale (VAS) score increase. X marks the mean and the line in the box the median.
Dovepress Fassov et al
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Discussion
In this interventional study investigating the mechanism of
action of SNM for IBS-D and IBS-M, we found no indica-
tions that SNM acts through modulation of the postprandial
response. We did find the tension to increase at baseline
after patients had consumed their meal indicating
a postprandial response. However, although the tension
levels recorded after the meal during the SNM period
were lower, the differences did not reach statistical signifi-
cance. Neither did we find any statistically significant dif-
ferences when comparing pressure, tension, or stretch ratio
at VAS 7 at baseline and at the end of the suprasensory SNM
period. Additionally, there was no statistically significant
difference when comparing the differences between
changes in tension, pressure, or stretch ratio before and
after the meal at baseline and at the end of the suprasensory
SNM period. Subdividing the patients into SNM responders
and non-responders we found no statistically significant
differences regarding tension, pressure, or stretch within
the groups. Comparing the groups, we surprisingly
observed that SNM responders were significantly more
compliant to stretch than non-responders before the meal
both at baseline and at the end of the suprasensory stimula-
tion period. The postprandial change was, however, non-
significant. Whether this may be a positive, prognostic
factor for a PNE success remains to be studied.
Figure 3 Change in stretch ratio to Visual Analog Scale (VAS) score increase. X marks the mean and the line in the box the median.
Fassov et al Dovepress
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Only few studies have investigated a given treatment´s
effect on the postprandial response in IBS patients. In
accordance with our present data, those previous studies
did not find that treatments, which reduced symptoms of
IBS, did so by changing the postprandial response. Thus,
Simrén and colleges found that hypnotherapy for IBS did
not lower the threshold to perception of gas and discom-
fort after a duodenal lipid infusion.18 In addition, they
observed significantly lower fasting balloon volumes
(increased sigmoid tone) in the hypnotherapy group com-
pared to the control group. In our study, patients were not
instructed to report perceptions of gas, but only vague
perception of moderate sensation, pain, and moderate
pain. Common to both studies, the given treatment had
no effect on the pain perceived by the patients following
a meal. In another recent study by Simrén et al, authors
found that the selective 5-HT3 receptor antagonist,
Alosetron, reduced pain following administration of duo-
denal lipids without having an effect on the postprandial
response.19
There are limitations to the present study. The sample
size calculation was based on the number needed to eval-
uate the treatment effect of SNM for IBS-D and IBS-M in
the previous published double-blinded, placebo-controlled
crossover study.9 However, subsequent power analysis for
tension, pressure, and stretch found a power of 0.81, 0.86,
Figure 4 Change in tension to Visual Analog Scale (VAS) score increase. X marks the mean and the line in the box the median.
Dovepress Fassov et al
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and 0.84 respectively, indicating the sample size was suf-
ficient to detect the specified effect.
Furthermore, the IBS patients in the study were chal-
lenged by consuming the entire standardized meal within
their given time period. Care was taken that the individual
consumed meal portions were comparable at baseline and
at the end of the suprasensory SNM period and we did see
a postprandial response at baseline. Finally, the study
relies on accurate patient reporting based on the visual
analog scale, although, multimodal stimulation data has
previously proven to be responsive to change.14
The mechanism of action of SNM may be
a combination of a direct efferent effect on the anal
sphincter complex and a modulation of afferent input to
the sacral spinal cord and/or supraspinal centers.11–13
Looking into the mode of action of SNM for IBS, our
group has previously published papers investigating the
effect on gastrointestinal motility, rectal sensitivity and
biomechanical properties. We found no effect of SNM on
gastric emptying or small intestinal transit patterns in
neither the fasting nor the postprandial state.20 We did,
however, observe a relaxation of the rectal wall associated
with a reduced IBS-specific symptom score and
a sensitization to stretch associated with a reduced con-
stipation domain score in the IBS-specific symptom
questionnaire.21 We were not able to reproduce those
data in the present study. This may be due to a lower
number of patients having a positive treatment effect of
SNM in the present study (fifteen versus twenty). It could
also be due to the SNM treatment length before investiga-
tion. Where the twenty-one patients in the initial study had
received SNM for a median of 5.8 months (1–20 months)
before multimodal impedance planimetry, it was only for 2
weeks in the present study. However, we did show
a positive effect on symptoms in both studies.
Tillisch et al have previously observed that patients
with IBS have a greater than normal engagement of
cerebral regions associated with emotional arousal and
endogenous pain modulation during rectal distensions.22
Furthermore, Haas et al have found impaired cerebral
processing of rectal stimuli and an altered cortical pro-
cessing of anal distention’s in fecal incontinence.23
Finally, Giani and colleagues have reported that pro-
longed latency of cerebral somatosensory evoked poten-
tials is a predictor of a positive treatment effect of SNM
for fecal incontinence. Therefore, they concluded, that
SNM might act on a cortical level via modulation of
the afferent pathway from the spinal nerves to the
sensory cortex.24 Thus, the authors propose that future
studies should investigate whether the positive treatment
effect of SNM for IBS is driven by changes in cerebral
function.
Further, it should be taken into consideration that
Griffin et al found that SNM increased the amplitudes of
evoked potentials in the sensory cerebral cortex during
anal stimulation in a recent rat study. Following sensation
of the electrophysiological experiments, the rat brains
were harvested and the group also found an association
between SNM and an up-regulation of the polysialylated
neuronal cell adhesion molecule indicative of neuronal
plasticity.25 The potential for neuromodulation during
SNM is indeed intriguing. In terms of research, it might
question whether PNE based and permanent SNM studies
are comparable. Furthermore, it may change the future
SNM treatment set-up from continuous to intermittent
and may not be lifelong.
Conclusion
The positive treatment effect of SNM for IBS-D and IBS-
M is not due to an altered postprandial response. Other
modes of action for the positive effect of SNM for IBS-D
and IBS-M should be sought.
Abbreviations
CSA, Cross-sectional area; IBS-D, Diarrhea-predominant
irritable bowel syndrome; GSRS-IBS, Gastrointestinal
Symptom Rating Scale – Irritable Bowel Syndrome; IBS,
Irritable Bowel Syndrome; IBS-M, Mixed irritable bowel
syndrome; MPDT, Moderate pain detection threshold;
PDT, Pain detection threshold; SNM, Sacral Nerve
Modulation; VAS, Visual analog scale.
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